Key result
Prophylactic anticoagulation with low molecular weight heparins or direct oral anticoagulants shows potential benefit in reducing venous thromboembolism risk in ambulatory patients with lung cancer.
Why the study?
Venous thromboembolism is common and thrombogenic in lung cancer, but primary thromboprophylaxis is not routinely recommended for all ambulatory cancer patients.
Does primary thromboprophylaxis reduce venous thromboembolism risk and improve overall survival in ambulatory patients with lung cancer?
Population
Ambulatory patients with lung cancer
Comparison
Primary thromboprophylaxis vs no thromboprophylaxis
Design
Narrative review
Authors
Loading...
May support prophylaxis consideration in ambulatory lung cancer; leaves open survival benefit and requires confirmatory RCTs.
Does primary thromboprophylaxis reduce venous thromboembolism risk and improve overall survival in ambulatory patients with lung cancer?
Primary thromboprophylaxis with LMWH or DOACs may reduce VTE risk and improve survival in ambulatory lung cancer patients, but further randomized trials are needed.
Dimakakos et al. (2020) conducted a review in Ambulatory patients with lung cancer. Prophylactic anticoagulation was evaluated on Venous thromboembolism risk reduction and overall survival. Prophylactic anticoagulation with low molecular weight heparins or direct oral anticoagulants shows potential benefit in reducing venous thromboembolism risk in ambulatory patients with lung cancer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: